Table 2 ROC analyses for prediction of mortality according to baseline (< 24 h of admission) biomarker concentration
Study | Mortality follow-up | AUC (95% CI) | Cutoff | Sn | Sp | PPV | NPV | LR+ | LR− |
|---|---|---|---|---|---|---|---|---|---|
Angiopoietins 1 and 2 | |||||||||
 Ang-2/Ang-1 ratio | |||||||||
  Fang [30] | 28 days | 0.845 (0.810 to 0.880) | 1.94 | 80% | 81% | 78% | 83% | 3.98 | 0.31 |
 Ang-1 | |||||||||
  Ricciuto [36] | 28 days | 0.620 (0.500 to 0.760) | – | – | – | – | – | – | – |
  Lin [32] | During hospital stay | 0.743 (0.726 to 0.847) | – | – | – | – | – | – | – |
  Fang [30] | 28 days | 0.778 (0.732 to 0.824) | – | – | – | – | – | – | – |
 Ang-2 | |||||||||
  Lin [32] | During hospital stay | 0.632 (0.515 to 0.750) | – | – | – | – | – | – | – |
  Kranidioti [31] | 28 days | 0.703 (0.578 to 0.827) | 9700 pg/ml | 42% | 82% | 51% | 76% | 2.32 | 0.49 |
  van der Heijden [38] | ICU mortality | 0.790 | 3066 pg/ml | 73% | 71% | 39% | 91% | 2.52 | 0.38 |
  Fang [30] | 28 days | 0.794 (0.750 to 0.837) | – | – | – | – | – | – | – |
  Palud [34] | 28 days | 0.960 (0.870 to 1.050) | 26,780 pg/ml | 100% | 93% | 83% | 100% | 14.29 | 0 |
HMGB1 | |||||||||
 Karlsson [42] | During hospital stay | 0.570 (0.470 to 0.670) | 6.5 ng/ml | 39% | 79% | 40% | 79% | 1.87 | 0.77 |
 Gibot [40] | 28 days | 0.610 | – | – | – | – | – | – | – |
sRAGE | |||||||||
 Bopp [50] | 28 days | – | 1569 pg/ml | 85% | 75% | 73% | 86% | 3.38 | 0.21 |
 Brodska [51] | 28 days | 0.660 (0.492 to 0.827) | 1804 pg/ml | 63% | 76% | 53% | 83% | 2.64 | 0.49 |
sTREM-1 | |||||||||
 Bayram [60] | not specified | 0.444 | 255 pg/ml | 50% | 40% | 50% | 40% | 0.83 | 1.25 |
 Suarez-Santamaria [56] | 28 days | 0.598 (0.520 to 0.676) | 55.7 pg/ml | 68% | 58% | 31% | 87% | 1.62 | 0.55 |
 Charles [61] | ICU mortality | 0.640 (0.540 to 0.740) | 954 pg/ml | 55% | 78% | 49% | 82% | 2.48 | 0.58 |
 Ravetti [47] | 28 days | 0.640 (0.460 to 0.830) | 750 pg/ml | 56% | 68% | 60% | 65% | 1.75 | 0.65 |
 Ravetti [47] | ICU mortality | 0.690 (0.510 to 0.870) | 750 pg/ml | 56% | 75% | 60% | 72% | 2.24 | 0.59 |
 Gibot [53] | 28 days | 0.740 (0.680 to 0.800) | 180 pg/ml | 86% | 70% | 59% | 91% | 2.87 | 0.20 |
 Su [58] | 28 days | 0.748 (0.637 to 0.860) | 0.499 | 63% | 84% | 81% | 54% | 4.01 | 0.43 |
 Brenner [62] | 90 days | 0.827 | 521 pg/ml | 71% | 86% | 87% | 79% | 4.99 | 0.33 |
 Li [59] | 28 days | 0.856 (0.784 to 0.929) | 252 pg/ml | 86% | 76% | 71% | 88% | 3.53 | 0.19 |
suPAR | |||||||||
 Suberviola [66] | During hospital stay | 0.670 (0.570 to 0.770) | 9.6 ng/ml | 81% | 46% | 39% | 85% | 1.49 | 0.43 |
 Giamarellos-Bourboulis [63] | 28 days | 0.708 (0.681 to 0.736) | 12.0 ng/ml | 62% | 69% | 36% | 87% | 1.99 | 0.55 |
 Khater [68] | 30 days | 0.720 (0.560 to 0.853) | 6.3 ng/ml | 79% | 63% | 76% | 67% | 2.11 | 0.33 |
 Donadello [67] | ICU and 28 days | 0.723 | 10.2 ng/ml | 71% | 65% | 38% | 88% | 2.03 | 0.45 |
 Zeng [72] | 28 days | 0.765 (0.658 to 0.872) | 12.0 ng/ml | 87% | 73% | 66% | 90% | 3.17 | 0.18 |
 Shan [70] | 90 days | 0.780 (0.630 to 0.930) | 310 pg/ml | 69% | 65% | – | – | – | – |
 Tsirigotis [71] | 28 days | 0.787 | 7.6 ng/ml | 82% | 73% | 63% | 88% | 3.04 | 0.25 |
 Liu [69] | 28 days | 0.788 (0.73 to 0.846) | 10.8 ng/ml | 85% | 78% | 39% | 97% | 3.79 | 0.19 |